JENNER VACCINE FOUNDATION
The aims of the Foundation are to undertake research and development aimed at the creation, testing and deployment of new vaccines against diseases of humans and livestock. The Foundation will have a particular focus on vaccines of the developing world where greatest needs exist for novel vaccines.
Objects
THE ADVANCEMENT OF EDUCATION AND IN PARTICULAR EDUCATION RESEARCH AND TRAINING IN THE FIELDS OF IMMUNOLOGY AND INFECTIOUS MALIGNANT OR OTHER CHRONIC DISEASES OR RELATED FIELDS OF MEDICINE SCIENCE AND TECHNOLOGY FOR THE DISCOVERY OR CREATION OF STRATEGIES FOR NOVEL VACCINES FOR THE PUBLIC BENEFIT
Financial health, per its FY2025 accounts
The accounts state that the Foundation reported a net surplus of £11,354 for the period ended 31 July 2025, driven by investment gains. Per the trustees' report, the charity operates on a low-cost basis with minimal administrative expenditure and holds unrestricted reserves of £457,771, which the trustees consider sufficient to manage timing fluctuations without undue financial risk.
What the accounts disclose
“It is the policy of the Board that the balance on unrestricted funds is maintained at such a level as is deemed sufficient to enable the Foundation to accommodate fluctuations in the timing of receipts and payments without exposing the Foundation to undue financial risk.” — page 7
“The Foundation has close working relationships with The Pirbright Institute and the University of Oxford. The Foundation occupies premises at the University of Oxford’s Old Road Campus site and any operational costs incurred by the University of Oxford are recharged to the Foundation.” — page 4
“The Foundation is a member of, and purchases discretionary mutual cover from, Oxford Mutual Limited. Oxford Mutual Limited is also a subsidiary of the University of Oxford.” — page 22
“The Foundation has close working relationships with The Pirbright Institute and the University of Oxford. The Foundation occupies premises at the University of Oxford’s Old Road Campus site and any operational costs incurred by the University of Oxford are recharged to the Foundation.” — page 4
“The Foundation is a member of, and purchases discretionary mutual cover from, Oxford Mutual Limited. Oxford Mutual Limited is also a subsidiary of the University of Oxford.” — page 22
“The Foundation has close working relationships with The Pirbright Institute and the University of Oxford. The Foundation occupies premises at the University of Oxford’s Old Road Campus site and any operational costs incurred by the University of Oxford are recharged to the Foundation.” — page 4
“The Foundation is a member of, and purchases discretionary mutual cover from, Oxford Mutual Limited. Oxford Mutual Limited is also a subsidiary of the University of Oxford.” — page 22
Policies the charity declares
- Conflicting interests
- Financial reserves policy and procedures
- Internal charity financial controls policy and procedures
- Internal risk management policy and procedures
- Investing charity funds policy and procedures
- Investment
- Trustee conflicts of interest policy and procedures
- Trustee expenses policy and procedures
Corporate structure
- Registered company of the charity Companies House 03079818
Funders the charity credits
- Wellcome Trust
- Medical Research Council UK
- European Commission
- Gates Foundation
- US NIH
- Foundation for the NIH
- International AIDS Vaccine Initiative
- UK Department of Health
- Malaria Vaccine Initiative at PATH
- Gates Malaria Programme at the London School of Hygiene and Tropical Medicine
- European Malaria Vaccine Initiative
- Lister Institute
- BBSRC
- DEFRA
- Wolfson Foundation
Company officers (Companies House)
- SCREATON, Gavin Robert, Professor on trustee list
- FLETCHER, Helen Alison, Dr on trustee list
- FRANCIS, Michael James, Dr on trustee list
- NAIR, Venugopal, Professor on trustee list
- CHARLESTON, Bryan, Dr on trustee list
- SALISBURY, David Maxwell, Professor on trustee list
- POLLARD, Andrew John, Professor Sir not on trustee list
- PRYOR, Sophia Elizabeth Sarah, Dr
Trustees
- Dr Bryan Charleston
- Dr Michael James Francis
- PROFESSOR DAVID MAXWELL SALISBURY
- Professor Gavin Robert Screaton
- Professor Helen Alison Fletcher
- Professor Sir Andrew Pollard FRS
- Professor Venugopal Nair
Income and spending
| Financial year end | Income | Spending |
|---|---|---|
| 31/07/2025 | £31k | £57k |
| 31/03/2024 | £21k | £45k |
| 31/03/2023 | £15k | £43k |
| 31/03/2022 | £14k | £35k |
| 31/03/2021 | £10k | £20k |
Common questions
Is JENNER VACCINE FOUNDATION financially healthy?
Per its FY2025 accounts: The accounts state that the Foundation reported a net surplus of £11,354 for the period ended 31 July 2025, driven by investment gains. Per the trustees' report, the charity operates on a low-cost basis with minimal administrative expenditure and holds unrestricted reserves of £457,771, which the trustees consider sufficient to manage timing fluctuations without undue financial risk. Its FY2025 accounts were audited by Gravita Audit Oxford LLP.